Primary information |
---|
sequence ID | Seq_167 |
Peptide sequence | ADGQPGAKGEPGDAGAKGDAGPPGP |
CancerPDF_ID | CancerPDF_ID10887, CancerPDF_ID10891, CancerPDF_ID10894, |
PMID | 21805675,21805675,21805675 |
Protein Name | Collagen alpha-1(I) chain,Collagen alpha-1(I) chain,Collagen alpha-1(I) chain |
UniprotKB Entry Name | CO1A1_HUMAN,CO1A1_HUMAN,CO1A1_HUMAN |
Fluid | Urine,Urine,Urine |
M/Z | 2189.9958,2206.0017,2221.9847 |
Charge | NA,NA,NA |
Mass (in Da) | NA,NA,NA |
fdr | NA,NA,NA |
Profiling Technique | MALDI-TOF,MALDI-TOF,MALDI-TOF |
Peptide Identification technique | MALDI-TOF-MS,MALDI-TOF-MS,MALDI-TOF-MS |
Quantification Technique | NA,NA,NA |
Labelled/Label Free | Label Free,Label Free,Label Free |
FDR | 1,1,1 |
CancerPDF_ID | CancerPDF_ID10887, CancerPDF_ID10891, CancerPDF_ID10894, |
p-Value | NA,NA,NA |
Software | NA,NA,NA |
Length | 25,25,25 |
Cancer Type | Muscle-invasive bladder cancer,Muscle-invasive bladder cancer,Muscle-invasive bladder cancer |
Database | SwissProt Database,SwissProt Database,SwissProt Database |
Modification | Oxidation: 22,"Oxidation: 11, 23","Oxidation: 5, 11, 23" |
Number of Patients | 751 bladder cancer and 127 control,751 bladder cancer and 127 control,751 bladder cancer and 127 control |
Regulation | Differentially expressed between cancer vs normal samples,Differentially expressed between cancer vs normal samples,Differentially expressed between cancer vs normal samples |
Validation | Mann-Whitney tests and areas under receiver-operator characteristic,Mann-Whitney tests and areas under receiver-operator characteristic,Mann-Whitney tests and areas under receiver-operator characteristic |
Sensitivity | NA,NA,NA |
Specificity | NA,NA,NA |
Accuracy | NA,NA,NA |
Peptide Atlas | NA |
IEDB | |
Primary information |
---|
sequence ID | Seq_170 |
Peptide sequence | ADGQPGAKGEPGDAGAKGDAGPpGP |
CancerPDF_ID | CancerPDF_ID3717, |
PMID | 27026199 |
Protein Name | Collagen alpha-1(I) chain |
UniprotKB Entry Name | CO1A1_HUMAN |
Fluid | Urine |
fdr | 2188.99 |
Profiling Technique | "CE-MS, Micro-TOF-MS" |
Peptide Identification technique | MS-MS |
Labelled/Label Free | Label Free |
CancerPDF_ID | CancerPDF_ID3717, |
p-Value | less than 0.05 |
Software | Proteome Discoverer 1.2 |
Length | 25 |
Cancer Type | Bladder cancer |
Database | Uniprot Human non-redundant Database |
Modification | p:Hydroxy-Proline |
Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
Regulation | Differentially expressed between recurrence of UBC vs recurrence control |
Validation | Independent Validation |
Sensitivity | For testing dataset 88% |
Specificity | For testing dataset 51% |
Accuracy | NA |
Peptide Atlas | NA |
IEDB | NA |
Primary information |
---|
sequence ID | Seq_171 |
Peptide sequence | ADGQpGAKGEpGDAGAKGDAGPPGp |
CancerPDF_ID | CancerPDF_ID3721, |
PMID | 27026199 |
Protein Name | Collagen alpha-1(I) chain |
UniprotKB Entry Name | CO1A1_HUMAN |
Fluid | Urine |
fdr | 2220.99 |
Profiling Technique | "CE-MS, Micro-TOF-MS" |
Peptide Identification technique | MS-MS |
Labelled/Label Free | Label Free |
CancerPDF_ID | CancerPDF_ID3721, |
p-Value | less than 0.05 |
Software | Proteome Discoverer 1.2 |
Length | 25 |
Cancer Type | Bladder cancer |
Database | Uniprot Human non-redundant Database |
Modification | p:Hydroxy-Proline |
Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
Regulation | Differentially expressed between recurrence of UBC vs recurrence control |
Validation | Independent Validation |
Sensitivity | For testing dataset 88% |
Specificity | For testing dataset 51% |
Accuracy | NA |
Peptide Atlas | NA |
IEDB | NA |
Primary information |
---|
sequence ID | Seq_173 |
Peptide sequence | ADGQpGAKGEpGDAGAKGDAGppGP |
CancerPDF_ID | CancerPDF_ID3723, |
PMID | 27026199 |
Protein Name | Collagen alpha-1(I) chain |
UniprotKB Entry Name | CO1A1_HUMAN |
Fluid | Urine |
fdr | 2236.98 |
Profiling Technique | "CE-MS, Micro-TOF-MS" |
Peptide Identification technique | MS-MS |
Labelled/Label Free | Label Free |
CancerPDF_ID | CancerPDF_ID3723, |
p-Value | less than 0.05 |
Software | Proteome Discoverer 1.2 |
Length | 25 |
Cancer Type | Bladder cancer |
Database | Uniprot Human non-redundant Database |
Modification | p:Hydroxy-Proline |
Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
Regulation | Differentially expressed between recurrence of UBC vs recurrence control |
Validation | Independent Validation |
Sensitivity | For testing dataset 88% |
Specificity | For testing dataset 51% |
Accuracy | NA |
Peptide Atlas | NA |
IEDB | NA |